Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with BRAF Mutation

키워드

참고문헌 (29)

1. 김상엽, "Cutaneous Melanoma in Asians", 전남의대학술지, 52(3), pp.185~193 (2016), 의과학연구소
2. [URL]
3. Wilson MA, "Molecular testing in melanoma", Cancer J, 18, pp.117~123 (2012)[DOI]
4. [URL]
5. Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)[DOI]
6. Rubinstein JC, "Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032", J Transl Med, 8, pp.67~ (2010)[DOI]
7. Edlundh-Rose E, "NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing", Melanoma Res, 16, pp.471~478 (2006)[DOI]
8. Saldanha G, "Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies", Clin Cancer Res, 12, pp.4499~4505 (2006)[DOI]
9. Lang J, "Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes", J Invest Dermatol, 125, pp.575~579 (2005)[DOI]
10. Jin SA, "BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas", J Invest Dermatol, 133, pp.579~582 (2013)[DOI]
11. 홍진우, "Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study", Annals of Dermatology, 26(2), pp.195~202 (2014), 대한피부과학회
12. Pearlstein MV, "Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma", J Cutan Pathol, 41, pp.724~732 (2014)[DOI]
13. Marin C, "Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility", Arch Pathol Lab Med, 138, pp.71~75 (2014)[DOI]
14. Capper D, "Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody", Acta Neuropathol, 122, pp.11~19 (2011)[DOI]
15. Long GV, "Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma", Am J Surg Pathol, 37, pp.61~65 (2013)[DOI]
16. Manfredi L, "Highly concordant results between immunohistochemistry and molecular testing of mutated V600E BRAF in primary and metastatic melanoma", Acta Derm Venereol, 96, pp.630~634 (2016)[DOI]
17. Capper D, "Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases", Acta Neuropathol, 123, pp.223~233 (2012)[DOI]
18. Yaman B, "BRAF-V600 Mutation heterogeneity in primary and metastatic melanoma: a study with pyrosequencing and immunohistochemistry", Am J Dermatopathol, 38, pp.113~120 (2016)[DOI]
19. Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)[DOI]
20. DePristo MA, "A framework for variation discovery and genotyping using next-generation DNA sequencing data", Nat Genet, 43, pp.491~498 (2010)
21. Van der Auwera GA, "From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline", Curr Protoc Bioinformatics, 43, pp.11~ (2013)
22. Wilm A, "LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets", Nucleic Acids Res, 40, pp.11189~11201 (2012)[DOI]
23. Wei Z, "SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data", Nucleic Acids Res, 39, pp.e132~ (2011)[DOI]
24. Hayward NK, "Whole-genome landscapes of major melanoma subtypes", Nature, 11(545), pp.175~180 (2017)
25. Wu X, "Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma", Oncol Lett, 14, pp.3601~3605 (2017)[DOI]
26. Boursault L, "Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing", PLoS One, 8, pp.e70826~ (2013)[DOI]
27. Rapisuwon S, "Discordance between cobas BRAF V600 testing and VE1 immunohistochemistry in a melanoma patient with bone marrow metastases", Am J Dermatopathol, 38, pp.687~689 (2016)[DOI]
28. Heinzerling L, "Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice", Br J Cancer, 108, pp.2164~2171 (2013)[DOI]
29. Ihle MA, "Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations", BMC Cancer, 14, pp.13~ (2014)[DOI]

관련 논문AI추천